504 results on '"Chronic diseases -- Drug therapy"'
Search Results
2. Researchers at Faculty of Medicine Target Cancer (The Role of Gut Microbiota in Modulating Cancer Therapy Efficacy)
3. Studies from Clalit Health Service Describe New Findings in Obesity [Effectiveness and Persistence of Anti-obesity Medications (Liraglutide 3 Mg, Lorcaserin, and Orlistat) In a Real-world Primary Care Setting]
4. Researchers from Guizhou Medical University Describe Findings in Type 2 Diabetes (Investigation of the Pharmacodynamic Components of * * Gastrodia elata* * Blume for Treatment of Type 2 Diabetes Mellitus through HPLC, Bioactivity, Network ...)
5. ASSESSMENT OF ADHERENCE TO TREATMENT IN PATIENTS WITH DIABETES MELLITUS TYPE 2 ACCOMPANIED BY A MULTIDISCIPLINARY TEAM/AVALIACAO DA ADESAO AO TRATAMENTO EM PACIENTES COM DIABETES MELLITUS TIPO 2 ACOMPANHADOS POR EQUIPE MULTIPROFISSIONAL/EVALUACION DE LA ADHERENCIA AL TRATAMIENTO EN PACIENTES CON DIABETES MELLITUS TIPO 2 ACOMPANADO DE UN EQUIPO MULTIDISCIPLINAR
6. J&J's TREMFYA approved by FDA for treatment of ulcerative colitis
7. Technological prospection study of the development of S1P1 modulator drugs for the multiple sclerosis treatment/Estudo de prospeccao tecnologica do desenvolvimento de farmacos moduladores S1P1 para o tratamento da esclerose multipla/Estudio de prospeccion tecnologica del desarollo de farmacos moduladores S1P1 para el tratamiento de la esclerosis multiple
8. KENNEDY SEEKS TO CHANGE US FOOD AND DRUG SYSTEM
9. Findings from Servier Laboratories Broaden Understanding of Personalized Medicine (Artificial Intelligence-driven Drug Development Against Autoimmune Diseases)
10. New Obesity Study Findings Have Been Reported by Investigators at National Institute for Diabetes and Digestive and Kidney Diseases (Approach To Obesity Treatment In Primary Care a Review)
11. Adicet Bio receives US FDA fast track designation for ADI-001 for class IV lupus nephritis
12. Researcher from Minhang Hospital Reports Details of New Studies and Findings in the Area of Nanoparticles (Plant-Derived Vesicle-like Nanoparticles: The Next-Generation Drug Delivery Nanoplatforms)
13. Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
14. STATEMENT ON THE NEED FOR THE CMS RULE ON COVERAGE OF OBESITY MEDICATIONS
15. Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
16. CONGRESS MUST ADDRESS AMERICA'S OBESITY CRISIS
17. PEGylated Proteins Market Set to Reach USD 19.1 Billion by 2031, Driven by Advancements in Drug Delivery: - Market Research Intellect
18. Metformin, a diabetes drug, may reduce the risk of prolonged COVID
19. Researcher at University of Lorraine Reports Research in Cardiovascular Diseases and Conditions (A Smooth Muscle Cell-Based Ferroptosis Model to Evaluate Iron-Chelating Molecules for Cardiovascular Disease Treatment)
20. New Reichman University study: Advances in cancer treatment and research: ChiTaRS 8.0 database of chimeric genes launched to facilitate the precise adaptation of treatments to specific cancer types
21. Investigators from New York University (NYU) Release New Data on Heart Failure (Approach To Estimating Adherence To Heart Failure Medications Using Linked Electronic Health Record and Pharmacy Data)
22. Research Institute of Virology Reports Findings in Multiple Sclerosis (A successful application of information technologies in the treatment of multiple sclerosis: a case report)
23. Research from Hospital and Research Center in the Area of Hypertension Described (A Cross Sectional Study on Adherence to Medication among Patients with Hypertension and/or Diabetes Attending One of the Tertiary Care Institutes of Ahmedabad ...)
24. Autonomous University Researcher Describes Recent Advances in Type 2 Diabetes (Association between medication adherence and health-related quality of life among type 2 diabetic adults in Mexico)
25. TREMFYA(r) (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
26. TREMFYA (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
27. American College of Lifestyle Medicine announces new CME/CE course on using food as medicine to achieve type 2 diabetes remission
28. How cystic fibrosis drug Trikafta has changed lives
29. 'New anti-obesity drugs allow for greater weight loss, reaching over 23%'
30. Policy that forced patients to switch to cheaper drugs saved province $730-million, report says
31. Eva Blázquez, endocrinologist of the Comprehensive Obesity Unit of Policlínica Gipuzkoa: 'The new anti-obesity drugs allow a greater weight loss, exceeding 23%'
32. What are the new treatments for obesity? by Percy Mayta-Tristán
33. Reports from Hospital Italiano Buenos Aires Provide New Insights into Psoriatic Arthritis (Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis)
34. TREMFYA® guselkumab receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
35. Chinese, Singaporean team leverages AI for diabetes diagnosis, treatment
36. Chinese, Singaporean team leverages AI for diabetes diagnosis, treatment
37. Dr. Stefie Deeds Featured in New York Times Article on Innovative Obesity Treatment Approach
38. Anti-obesity Medication Market Analysis 2024-2034 by Product, Mechanism of Action, Distribution Channel and Region - Global Industry Projected to Register 31.71% CAGR, Reaching $137.4 Billion by 2034
39. Dr. Stefie Deeds Featured in New York Times Article on Innovative Obesity Treatment Approach
40. Peru : SIS financed more than one million diabetes care treatments for its insured nationwide
41. Female Sexual Dysfunction Treatment Market size is set to grow by USD 21.69 billion from 2024-2028, increasing prevalence of chronic diseases boost the market
42. Female Sexual Dysfunction Treatment Market size is set to grow by USD 21.69 billion from 2024-2028, increasing prevalence of chronic diseases boost the market, Technavio
43. A potential complementary treatment for patients with Parkinson's disease: Stimvia carries out a pilot study and announces promising initial results
44. Possible complementary treatment for patients with Parkinson's disease: Stimvia
45. Possible additional treatment for patients with Parkinson's disease: Stimvia completes pilot study and announces promising initial results
46. Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
47. Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
48. Novo Nordisk, the pharmaceutical company at the forefront of diabetes and obesity, expands operations in Chile and prepares new products
49. Sick, those who suffer from lack of drug supply
50. Weight-loss drugs 'make users lose muscle'. AstraZeneca boss claims rivals' treatments to reduce obesity such as Wegovy do not just shrink fat
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.